Patents by Inventor Carol L. Ensinger

Carol L. Ensinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20090221821
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.
    Type: Application
    Filed: February 10, 2009
    Publication date: September 3, 2009
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Carol L. Ensinger, James E. Dowling, Russell C. Petter, Gnanasambandam Kumaravel
  • Adenosine receptor antagonists and methods of making and using the same
    Patent number: 7579354
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.
    Type: Grant
    Filed: July 10, 2006
    Date of Patent: August 25, 2009
    Inventors: William F. Kiesman, Carol L. Ensinger, Russell C. Petter, James E. Dowling, Gnanasambandam Kumaravel, He Xi Chang, Ko Chung Lin
  • Cell adhesion inhibitors
    Patent number: 6949534
    Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: September 27, 2005
    Assignee: Biogen Idec MA Inc.
    Inventors: Zhongli Zheng, Carol L. Ensinger, Steven P. Adams
  • Adenosine receptor antagonists and methods of making and using the same
    Publication number: 20040067966
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.
    Type: Application
    Filed: August 21, 2003
    Publication date: April 8, 2004
    Applicant: Biogen, Inc.
    Inventors: William F. Kiesman, Carol L. Ensinger, Russell C. Petter, James E. Dowling, Gnanasambandam Kumaravel, He Xi Chang, Ko Chung Lin
  • Cell adhesion inhibitors
    Publication number: 20040053907
    Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.
    Type: Application
    Filed: October 1, 2002
    Publication date: March 18, 2004
    Applicant: Biogen, Inc. a Massachusetts Corporation.
    Inventors: Zhongli Zheng, Carol L. Ensinger, Steven P. Adams
  • Cell adhesion inhibitors
    Patent number: 6686350
    Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.
    Type: Grant
    Filed: January 25, 1999
    Date of Patent: February 3, 2004
    Assignee: Biogen, Inc.
    Inventors: Zhongli Zheng, Carol L. Ensinger, Steven P. Adams
  • Adenosine receptor antagonists and methods of making and using the same
    Publication number: 20030225038
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.
    Type: Application
    Filed: June 12, 2003
    Publication date: December 4, 2003
    Applicant: Biogen, Inc.
    Inventors: Carol L. Ensinger, James E. Dowling, Russell C. Petter, Gnanasambandam Kumaravel
  • Adenosine receptor antagonists and methods of making and using the same
    Patent number: 6649600
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be usefull in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula I: wherein: R3 is an optionally substituted bicyclic, tricylic, or pentacyclic group selected from:  and wherein R1, R2, R6, X1, X2, and Z are as described in the specification.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: November 18, 2003
    Assignee: Biogen, Inc.
    Inventors: William F. Kiesman, Carol L. Ensinger, Russell C. Petter, James E. Dowling, Gnanasambandam Kumaravel, He Xi Chang, Ko Chung Lin
  • Adenosine receptor antagonists and methods of making and using the same
    Patent number: 6605600
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula I: R3 is an optionally substituted group selected from: and wherein X1, X2, Z, R1, R2, and R6 are as described in the specification.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: August 12, 2003
    Assignee: Biogen, Incorporated
    Inventors: Carol L. Ensinger, James E. Dowling, Russell C. Petter, Gnanasambandam Kumaravel
  • Imidazole 5-position substituted angiotensin II antagonists
    Patent number: 5545651
    Abstract: Novel substituted imidazoles of Formula (I), which are useful as angiotensin II antagonists, are disclosed: ##STR1##
    Type: Grant
    Filed: November 28, 1994
    Date of Patent: August 13, 1996
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: John J. V. Duncia, Carol L. Ensinger, Richard E. Olson, Mimi L. Quan, Joseph B. Santella, III, Mary K. Vanatten
  • Imidazole 5-position substituted angiotensin II antagonists
    Patent number: 5395844
    Abstract: Novel substituted imidazoles of Formula (III), which are useful as angiotensin-II antagonists, are disclosed: ##STR1## These compounds, exemplified by the compound 1-((2'-((i-Amyloxycarbonylamino)sulfonyl)-3-fluoro-(1,1'-biphenyl)-4-yl)me thyl)-5-[2-(N-butyryl-N-pyridin-3-ylamino) ethylcarbonyl]-4-ethyl-2-propyl-1H-imidazole, are useful as antihypertensive agents.
    Type: Grant
    Filed: June 10, 1993
    Date of Patent: March 7, 1995
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: John J. V. Duncia, Carol L. Ensinger, Richard E. Olson, Mimi L. Quan, Joseph B. Santella, III, Mary K. Vanatten
  • Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
    Patent number: 5310929
    Abstract: Prodrugs of imidazole carboxylic acids which are AII antagonists useful in treating hypertension, pharmaceutical compositions thereof and a method of treating hypertension using such prodrugs are disclosed.
    Type: Grant
    Filed: August 6, 1992
    Date of Patent: May 10, 1994
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: Robert J. Ardecky, Carol L. Ensinger, James R. Pruitt